Seracal
Vytala, a healthcare-focused food technology company based in Downingtown, Pennsylvania, has announced pivotal developments regarding its innovative medical food, SeracalTM. Designed to address issues related to fat malabsorption, Seracal is gaining traction in the medical community, with reported monthly sales growth exceeding 30%. This surge is attributed to increasing clinician demand, patient necessity, and broad coverage by U.S. insurance providers.
The company is set to showcase Seracal at two major medical conferences on October 12, 2025. At the FNCE 2025 in Nashville, Dr. Carol Ireton-Jones, a leading expert in adult dietetics, will present research titled “Can Fat Absorption Be Enhanced with a Novel Medical Food?” This presentation will include two case studies demonstrating Seracal’s clinical efficacy. One study details a pediatric patient diagnosed with VACTERL association and short bowel syndrome, who experienced notable weight gain and improvement in gastrointestinal (GI) symptoms after utilizing Seracal. The second study discusses a patient suffering from pancreatic cancer and cachexia, who reported significant weight gain, reduced GI discomfort, and fewer acute pancreatitis episodes, ultimately enhancing their quality of life.
At the PIONEER Symposium in St. Louis, Dr. Sivan Kinberg, a Pediatric Gastroenterologist at Columbia University Medical Center, will present a case report on a 5-year-old patient with short bowel syndrome. Within six weeks of starting Seracal, the patient achieved substantial weight gain and a reduction in GI symptoms, showcasing the food’s potential effectiveness in pediatric applications.
Additionally, Vytala has secured approval for an Institutional Review Board (IRB) study at Broward Health in South Florida, led by Dr. Debora Duro, MD, MS, who oversees Pediatric Gastroenterology, Hepatology and Nutrition at Salah Foundation Children’s Hospital. This retrospective analysis will assess outcomes in approximately 30 pediatric GI patients treated with Seracal, with results anticipated in 2026. Dr. Duro remarked, “We are seeing wonderful outcomes across a wide range of patients. This analysis will help define Seracal’s role in clinical practice beyond exocrine pancreatic insufficiency.”
Seracal is built upon the innovative science of Lym-X-Sorb®, a groundbreaking fat absorption technology developed by Dr. David Yesair of BioMolecular Products, Inc. With over $30 million invested in its development, including a $7 million grant from the National Institutes of Health for clinical trials, Lym-X-Sorb has shown statistically significant improvements in body mass index (BMI), fat-soluble vitamin absorption, and overall patient tolerance among individuals with cystic fibrosis and exocrine pancreatic insufficiency. Vytala has obtained exclusive worldwide rights to this proprietary formulation and has further refined it for enhanced taste, palatability, and stability.
Dr. Kinberg highlighted the critical role of Seracal, stating, “For a child with short bowel syndrome who was severely malnourished and facing a return to parenteral nutrition, Seracal provided a critical breakthrough. It supported weight gain when other options had failed and helped this patient avoid parenteral nutrition. This case underscores the broader potential of Seracal to improve outcomes and quality of life for children with short bowel syndrome.”
In conjunction with these initiatives, Vytala is conducting a multi-center prospective study led by Dr. Ireton-Jones to evaluate Seracal’s outcomes across a wider patient population. The trial is focused on tracking GI symptoms, weight gain, and growth in patients aged one and older. “While individual patient experiences are encouraging, further studies are essential to advance clinical care,” Dr. Ireton-Jones noted. “We believe Seracal’s unique mechanism will benefit patients with a wide range of GI conditions, and early data is demonstrating positive outcomes as well as valuable insights.”
Seracal is currently available nationwide and is covered by most major healthcare insurers. Vytala is dedicated to advancing nutritional solutions and aims to address the widespread issue of malabsorption, building on a foundation of over 100 years of collective experience in clinical nutrition, food science, and healthcare reimbursement. The company’s commitment to innovation includes the development of a suite of precision nutrient products aimed at tackling nutrient deficiencies in both humans and animals.
